Market Newsdesk

VANCOUVER, British Columbia, and BOSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Imagin Medical (CSE: IME) (OTC: IMEXF) (FRA: DPD2) (the “Company”) announces that critical milestones met in the second half of 2020 will support the Company in achieving its 2021 goals.

Like most companies during 2020, Imagin had to adapt to the unexpected circumstances surrounding COVID-19. The Company implemented emergency measures to decrease expenses in all areas of the business to extend its cash runway. Key salaries were reduced by over 50% company-wide, employee travel was frozen, and all meetings were held virtually. These measures remain in place.

Despite the constraints, Imagin reached a major milestone with the successful transition from the product development stage to manufacturing with the selection of Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract manufacturer with expertise in the manufacture of full, state-of-the-art imaging systems for minimally invasive surgeries.

“Our relationship with Lighthouse Imaging marks a new stage in the Company’s progress,” remarked Jim Hutchens, Imagin’s president and CEO. “We anticipate 2021 to be a breakout year with emphasis on manufacturing and the FDA process. This year’s primary goal is the completion of the final pre-production i/Blue Imaging System unit. The Company’s secondary goal is to establish final test parameters with the FDA, as we will continue to build relationships with clinical opinion leaders and expand our IP Platform.”

In the fourth quarter of 2020, Imagin signed a $3 million Convertible Note term sheet and closed the first tranche of $750,000. The Company is planning on additional closings in January, February and March to complete this financing.  Imagin intends to utilize the funds raised to support product optimization for manufacturing, as well as the ongoing FDA approval process and market awareness.

Other activities planned for 2021 include participating in the American Urology Association (“AUA”) Annual Meeting in the third quarter, to introduce the final pre-production i/Blue Imaging System to key clinical opinion leaders and the broader medical community.

To further communicate the Company’s message, Imagin delivered its first webinar  in October 2020 featuring two world-renowned urologists, Dr. Ashish Kamat from MD Anderson Cancer Center in Houston and Dr. Alexandre Zlotta from Mt. Sinai Hospital in Toronto, who discussed Blue Light Cystoscopy and its limitations. This was followed by a demonstration of how the i/Blue System will address the market’s current needs.

Imagin plans to continue non deal road shows that will elevate the Company’s visibility in the U.S., CA and the EU and expand its investor base by working with Torrey Hills Capital (THC) where Imagin will increase awareness through THC established relationships with investment professionals, investment advisors and money managers focused on the microcap market space.

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal and help reduce recurrence rates. Imagin’s initial target market is bladder cancer, the sixth most common cancer in the U.S. and the third most common cancer in men. Worldwide, over 380,000 new cases are diagnosed each year. With treatment costs of $4 billion per year in the U.S. alone, bladder cancer is the most expensive cancer to treat during the lifetime of a patient, with approximately 60% of the costs attributable to recurrence. Over 80,000 new cases each year and almost 600,000 patients in the U.S. living in fear of their bladder cancer returning represent a large market that can benefit from the Company’s i/Blue Imaging technology. Learn more at www.ImaginMedical.com.

Forward-Looking Statements


Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual, and future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Contact:

Jim Hutchens
President and CEO
Telephone: 833-246-2446

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in critical communications systems and solutions, today announced it has opened offices in Singapore and Dubai as part of the Company’s ongoing regional expansion. The offices are staffed with business development professionals with extensive regional sales experience in Southeast Asia, the Middle East, Africa and Central Asia.

“While the pandemic has severely impacted international business travel, in-person meetings and trade shows, it has significantly increased interest in mass notification solutions and LRAD^® systems,” said Richard S. Danforth, Chief Executive Officer, Genasys Inc. “To meet the growing demand in these regions, we have invested in experienced sales leaders to accelerate business development and work with representatives, resellers and prospective customers.”

Sean McKane is serving as Vice President of Business Development for Southeast Asia. Mr. McKane served as the Asia Pacific Sales Director for Federal Signal Corporation from 2008 – 2013 and 2015 – 2017 before accepting the same position with Vigilant Solutions (A Motorola Solutions Company). From 2013 – 2015, he was Country Manager for Eaton Corporation’s Hazardous Area Communications division in Australia. Mr. McKane served as Sales Manager and National Sales Director from 2004 – 2008 for Australian telecom carriers Optus Uecomm, a wholly owned subsidiary of Singapore Telecommunications, and Allegro Networks Australia, respectively.

Peter Ayre is serving as Vice President of Business Development for the Middle East, Africa and Central Asia. Mr. Ayre served as Motorola Solution’s Regional Sales Director in the Middle East from 2017 – 2020. His sales responsibilities included public safety voice and data solutions, Command & Control infrastructure and multiple Smart City solutions. Mr. Ayre previously served as Regional Sales Manager in the Middle East, North Africa and Central Asia regions for Harris Corporation from 2009 – 2017, where he was responsible for sales of tactical communications and public safety infrastructure, and C4i, ISR and border security networks.

“Establishing in-region offices is essential for the growth of Genasys’ business initiatives throughout the world,” continued Mr. Danforth. “Additional international offices are planned.” 
The Company also announced the appointment of Mauricio Tellez as Vice President of Business Development for Latin America. Mr. Tellez served as Regional Managing Director for L3 Harris Technologies/Communication Systems division in the Caribbean and Latin America from 2017 – 2019, Senior Regional Manager from 2007 – 2017, and Major Account Manager from 2004 – 2007. From 1996 – 2003, he served as Regional Director for Titan Corporation/Datron World Communications Division in Latin America and Europe.

Genasys^™ is a global provider of critical communications systems and solutions to help keep people safe. Based in San Diego with additional offices in Madrid, Ottawa, Singapore and Dubai, Genasys provides a multi-channel approach to deliver geo-targeted alerts, notifications, instructions and information before, during and after public safety threats and critical business events. The Company’s unified critical communications platform includes Genasys Emergency Management (GEM) applications, National Emergency Warning Systems (NEWS), LRAD^® long-range voice broadcast systems and more.

About Genasys Inc.

Genasys systems are in service in 72 countries in a range of diverse applications, including public safety, emergency warning, mass notification, critical event management, defense, law enforcement, homeland security, and many more. For more information, visit genasys.com.

Forward-Looking Statements

Except for historical information contained herein, the matters discussed are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on these statements. We base these statements on particular assumptions that we have made in light of our industry experience, the stage of product and market development as well as our perception of historical trends, current market conditions, current economic data, expected future developments and other factors that we believe are appropriate under the circumstances. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, including without limitation the business impact of health crises or outbreaks of disease, such as epidemics or pandemics, and other risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. Risks and uncertainties are identified and discussed in our filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management’s expectations as of the date hereof. Future results may differ materially from our current expectations. For more information regarding other potential risks and uncertainties, see the “Risk Factors” section of the Company’s Form 10-K for the fiscal year ended September 30, 2020. Genasys Inc. disclaims any intent or obligation to update those forward-looking statements, except as otherwise specifically stated.

Investor Relations Contacts
Jim Fanucchi and Satya Chillara
Darrow Associates, Inc.
[email protected]

TORONTO, Jan. 13, 2021 (GLOBE NEWSWIRE) — Worksport Ltd (OTC: WKSP) (or the “Company”) has received Official Notice from the U.S. Patent and Trademark Office that its filing for trademark protection for TerraVis COR™, its line of mobile battery packs, has been accepted, entitling the Company to use the trademark symbol in the U.S. for its innovative, soon-to-be-launched mobile battery system. The TerraVis COR™ line, a consumer-oriented extension of Worksport’s TerraVis™ innovative solar-powered advanced folding truck bed tonneau cover system, is the first in the industry. This marks the Company’s entrance into the broader consumer goods market, since the COR battery system can be purchased and used without the TerraVis solar tonneau cover.  

The U.S. filing notice precedes publication in in the U.S. Patent and Trademark Office’s Official Gazette. This publication provides notice by the Patent and Trademark Office that a mark has been at least preliminarily approved for registration. Once the mark clears this process and is approved, the company may then also use the ® mark.

The TerraVis Cor™ mobile battery system is a patented modular battery storage technology product developed in conjunction with TerraVis™ solar tonneau covers. The entire system is a fusion of cutting-edge solar power generation, storage, and delivery applicable to numerous consumer goods and needs, not just the light (pickup) truck market. TerraVis™ Cor energy system is a stand-alone portable unit that goes beyond its original intended usage of powering workplaces and campsites. Now the same system has a range of applications that is a perfect complement for our IoT centric lifestyle and connected world and will be available for sale through retail and online channels. The TerraVis Cor battery system is the first modular, scalable, mobile power generator and inverter system of its kind. Offering the owner off-grid powder with replaceable batteries. The battery packs can be charged by solar panels, 12V, or standard wall outlets.

“Worksport is beginning 2021 with a big bang,” said Worksport CEO Steven Rossi. “First, we announced initial proceeds of US$1.1 Million from our ongoing Regulation A public offering and now we’ve added to our Intellectual Property Portfolio of over 30 patents and trademarks. The TerraVis COR battery system marks our entry into a broader market, not just the pickup truck owner market. The TerraVis COR system will appeal to any one of the 300+ million Americans who need a mobile power system for emergency use, the campsite, or a jobsite. This market is huge and we’re excited to be entering broader markets with such a disruptive product.”

Rossi also said the Company’s work with Hercules Electric Mobility Inc., to be a Tier One OEM supply partner for its forthcoming Alpha Electric Pickup continues to advance rapidly, partnered with Nissan. In addition, Worksport is still moving forward the second agreement entered into with Atlis Motor Vehicles, Mesa, Ariz., aimed at configuring the TerraVis™ solar charging system as an OE accessory for the highly anticipated, technologically advanced Atlis XT electric pickup truck.

“Worksport has rapidly matured as a company, now with four revenue streams and additional Reg A capital.” said Rossi. “First there was our technologically original tonneau cover line, then our customized non-competitive private label line, then TerraVis™ became part of Worksport and attracted the interest of two important EV companies. Then finally there is the development and launch of the TerraVis COR™ mobile battery system, which positions us in the multi-billion retail, automotive supply and online markets. We believe that the year ahead will be a transformative year for Worksport, as we have just begun.”

Worksport’s Regulation A offering is still open at www.invest.worksport.com – any interested investors are encouraged to participate in this opportunity before it closes. Minimum investment is $2000, and all securities purchased are registered and tradeable. Investors have an opportunity to purchase one common share and one 12-month warrant, directly from the Company. Investors are encouraged to view the company’s newest investor presentation at: https://presentation.worksport.com/

Any interested investors or shareholders are also encouraged to follow the company’s social media accounts on Twitter, Facebook, LinkedIn, and Instagram, as well as sign up for the company’s newsletters on both www.worksport.com and www.goterravis.com, to stay up to date on all of the latest news. Worksport will continue to update shareholders, supporters, and investors to maintain the highest level of disclosure and information dissemination as Worksport continues to grow and develop at a very rapid pace.

About Worksport Ltd.

Worksport Ltd., an innovative manufacturer of high quality, functional, and aggressively priced tonneau covers for light trucks like the F150, Sierra, Silverado, Canyon, RAM, and Ford F-Series. For more information, please visit www.worksport.com. Currently listed on the OTCQB Market under the trading symbol “WKSP.”

Connect with Worksport:

LinkedIn



Facebook



Twitter



Instagram

For further information please contact:

Mr. Steven Rossi
CEO & Director
Worksport, Ltd
T: 1-888-554-8789
E: [email protected]

Forward-Looking Statements

This document may contain forward-looking statements, relating to Worksport, Ltd. operations or to the environment in which it operates, which are based on Franchise Holdings International Inc. operations, estimates, forecasts and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, and/or are beyond Worksport, Ltd.’s ’s control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Consequently, readers should not place any undue reliance on such forward-looking statements. Worksport, Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No Stock Exchange or Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Corporate rebrand reflects enhanced focus on specialty alcohols and essential ingredients

SACRAMENTO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Pacific Ethanol, Inc. (NASDAQ: PEIX), a leading producer of specialty alcohols and essential ingredients, has changed its corporate name to Alto Ingredients, Inc., effective January 12, 2021. The company’s name change will be reflected on The Nasdaq Stock Market on January 14, 2021, and the company’s stock will begin trading under a new ticker symbol, ALTO, starting February 1, 2021.

CEO Mike Kandris said, “We have chosen our new corporate name and brand to represent our many high-quality products, which our customers incorporate into a range of vital finished goods that touch people’s everyday lives, from cleaning solutions to pharmaceuticals. We are capitalizing on our unique capability to manufacture high-grade alcohols for the food, beverage, health, and ingredients markets, and to process corn into high protein feed, pet food, and renewable fuel. As we move forward under our new Alto Ingredients brand, we remain committed to our goal of delivering the highest levels of integrity, purity, and quality to create value for our customers, partners, and shareholders.”

About Alto Ingredients, Inc.

Alto Ingredients, Inc. (PEIX), formerly known as Pacific Ethanol, Inc., is a leading producer of specialty alcohols and essential ingredients. The company is focused on products for four key markets: Health, Home & Beauty; Food & Beverage; Essential Ingredients; and Renewable Fuels. The company’s customers include major food and beverage companies and consumer products companies. For more information please visit www.altoingredients.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements and information contained in this communication that refer to or include Alto Ingredients’ estimated or anticipated future results or other non-historical expressions of fact are forward-looking statements that reflect Alto Ingredients’ current perspective of existing trends and information as of the date of the communication. Forward looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions. Such forward-looking statements include, but are not limited to, statements concerning Alto Ingredients’ plans, objectives, expectations and intentions. It is important to note that Alto Ingredients’ objectives, expectations and intentions are not predictions of actual performance. Actual results may differ materially from Alto Ingredients’ current expectations depending upon a number of factors affecting Alto Ingredients’ business. These factors include, among others, adverse economic and market conditions, including for specialty alcohols and essential ingredients; export conditions and international demand for the company’s products; fluctuations in the price of and demand for oil and gasoline; raw material costs, including production input costs, such as corn and natural gas; and the effects – both positive and negative – of the novel coronavirus, COVID-19. These factors also include, among others, the inherent uncertainty associated with financial and other projections; the anticipated size of the markets and continued demand for Alto Ingredients’ products; the impact of competitive products and pricing; the risks and uncertainties normally incident to the specialty alcohol production and marketing industries; changes in generally accepted accounting principles; successful compliance with governmental regulations applicable to Alto Ingredients’ distilleries, products and/or businesses; changes in laws, regulations and governmental policies; the loss of key senior management or staff; and other events, factors and risks previously and from time to time disclosed in Alto Ingredients’ filings with the Securities and Exchange Commission including, specifically, those factors set forth in the “Risk Factors” section contained in Alto Ingredients’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 16, 2020.

Media Contact:                 
Bryon McGregor, Alto Ingredients, Inc., 916-403-2768, [email protected]

Company IR Contact:                 
Michael Kramer, Alto Ingredients, Inc., 916-403-2755, [email protected]

IR Agency Contact:
Moriah Shilton, LHA Investor Relations, 415-433-3777, Investorrelations@altoingredients.com

 

ST. LOUIS, Jan. 13, 2021 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today announced that Dae Gon Ha, Ph.D., has joined the firm as a Director and Equity Research Analyst covering the biotechnology sector. He is based in the firm’s Boston office.

Dr. Ha most recently served as a Vice President in biotechnology research at BTIG. Prior to BTIG, he was Vice President in biotechnology research at SVB Leerink, where he focused on rare disease companies. Dr. Ha completed his post-doctoral research fellowship at Harvard Medical School, where he initiated, designed, and executed a chemical compound screen with the goal of identifying novel antibiotics. He received a Ph.D. in Microbiology and Immunology from Dartmouth College and a B.A. in Biology from Grinnell College.

“We are thrilled to welcome Dae Gon to Stifel, as we continue to extend our leading biotech franchise,” said Keith Gay, Director of Research. “Innovation and investment into next-generation medicines and therapies have never been more important or appreciated, and we are dedicated to providing clients with expert analysis and actionable ideas in this key sector.”

Dr. Ha will help strengthen Stifel’s research presence in the rapidly growing healthcare sector, which is currently the second largest sector in the S&P 500. With this hire, Stifel has a global research team of 52 healthcare professionals, including 19 senior analysts, covering 235 companies within the biotechnology, healthcare providers, medical technology & supplies, and specialty pharmaceutical subsectors.

Stifel Company Information

Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries. Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC and Century Securities Associates, Inc. The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities.  Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions.  Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services.  To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit https://www.stifel.com/investor-relations/press-releases.

Media Contacts

Neil Shapiro, (212) 271-3447
[email protected]

Jeff Preis, (212) 271-3749
[email protected]

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations), announces today that it has signed a new distribution agreement with L1 Enterprises, a leading provider of medical equipment and supplies to the government marketplace including the Department of Defense (DOD), Department of Veterans Affairs (VA), Health and Human Services (HHS) and the National Institute of Standards and Technology (NIST). Daxor and L1 Enterprises will work together to provide Daxor’s BVA-100 (Blood Volume Analysis) diagnostic blood test (“BVA”), driving the use of BVA to help guide precise, individualized volume management in a wide variety of medical conditions including heart failure and critical care.

“Partnering with L1 Enterprises will help accelerate a much needed and valuable test to those who have served and continue to serve our country,” said Michael Feldschuh, CEO and President of Daxor. “Combining our sales and marketing efforts will facilitate awareness, adoption and integration of our BVA technology into standard of care, leading to better outcomes and quality of life for veterans.”

“L1 Enterprises is excited to join forces with Daxor,” said C. Toby Calvo, U.S. Naval Officer, CEO and President of L1 Enterprises. “Their clinically proven blood volume measurement technology will help to reduce mortality rates of our nation’s veterans and warfighters while providing significant cost savings for the Federal Government.”

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100^® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.

About L1 Enterprises

Established in 2007, L1 Enterprises is a distributor of medical equipment and supplies to Federal Healthcare and Research Facilities across the country. As a verified Service Disabled Veteran Owned Small Business, L1 represents gold standard manufacturers whose product lines support all healthcare disciplines. L1 Enterprises’ customers include but are not limited to the Department of Defense (all agencies), Veterans Affairs, National Institutes of Health, Indian Health Services, & National Institute of Standards and Technology.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
[email protected]

Tulsa, OK, Jan. 13, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — AppSwarm, Corp. (OTC: SWRM), a software development company and aggregator of mobile applications, announces joint venture with DeepSkyConnect to offer video conferencing solutions to the financial industry.

SwarmConnect, in conjunction with DeepSkyConnect and Corporate Roadshow, announces the launch of video conferencing, or ‘virtual advisory’ services, for the investment and financial industry.

Virtual Advisory Services

While phone calls to discuss potential funding deals can work to some degree, humans are visual creatures, and ultimately, we want to see and be able to talk to someone face-to-face.

The integration of video conferencing in client relations can also open the door, on a global scale, for financial advisory firms to new types of clientele that advisors have not traditionally served.

Investor Communication and Virtual Conferences

In partnership with Corporate Roadshow, we are also launching a host of video conferencing solutions to include:

– Company Video Calls (earnings)
– Investor Webinars (PowerPoint)
– Annual Shareholder Meetings
– Virtual Investor Conferences
– New Product Launches and Demos
– Reg A and 506(c) Presentations

Corporate Roadshow Management has over 30 years’ experience in the capital and financial markets and will lead the team project of building video conferencing services for companies in both the public and private markets. For more information visit www.corporateroadshow.com

Institutional Investment Firms

DeepSkyConnect will be targeting video conferencing services to such areas as securities lawyers, private equity and investment banking firms, and family offices. AppSwarm will assist in developing marketing, branding, customer support, and client relations with these firms.

Financial firms or potential investors interested in learning more about this project please visit https://www.deepskywireless.com/investors/

Work from Home Solution

As our economy transforms, more financial companies and employees have been integrating video conferencing technology as a work from home solution. AppSwarm will aim to provide its video conferencing platform to companies who wish to integrate work from home and collaboration solutions into their business operations, while also striving for the safety of their employees and customers alike.

FREE Trial Service

Financial or securities law firms interested in trying out the service can ‘signup’ for a 14-day free trial at https://www.deepskywireless.com/conferencing/signup/

About APPSWARM

AppSwarm is a technology company specializing in accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.

For more information, visit us at www.app-swarm.com or follow us on www.facebook.com/AppSwarm  Twitter https://twitter.com/AppSwarm or Instagram https://www.instagram.com/appswarm/

Forward-Looking Statements:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company’s filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

AppSwarm, Corp.
888-886-8583
[email protected]

Corporate Roadshow
631-327-0084
[email protected]

MIAMI and NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) — Kaseya®, the leading provider of IT and security management solutions for managed service providers (MSPs) and small to medium-sized businesses (SMBs), announced today that the company grew by over 20% and saw record earnings in 2020, driven by its unparalleled commitment to customers during the worst economy in modern history.

In response to the impact that COVID-19 had on the industry, Kaseya has continued to expand IT Complete, its workflow integrated platform of IT solutions, to ensure customers have constant access to the most cutting-edge solutions. With more than 78 workflow integrations and a bevy of new product innovations, IT Complete is the industry’s most comprehensive, fully integrated IT and security management platform available.

The company also launched Kaseya Cares, a COVID-19 assistance program that helped businesses navigate government relief programs and provides access to direct financial assistance and complimentary business guidance and assistance via Kaseya Powered Services. To date, the program has assisted more than 4,500 customers and provided over $10 million in direct financial relief.

“2020 was an incredible year of change that provided tremendous opportunity for IT service providers,” said Fred Voccola, CEO of Kaseya. “Though economies around the world struggled, people relied on technology more than ever before. This demand transformed IT service providers into essential workers, who became indispensable in helping SMBs keep their businesses running. As COVID-19 has accelerated this digital transformation for SMBs and business owners recognize that this new normal is here to stay, SMB IT spending will continue to increase and place greater demands on IT service providers. This surging trend means that IT teams will need a robust, comprehensive, workflow integrated IT and security management solution to meet the many demands of their customers, and there is no better solution in the market than the Kaseya IT Complete Platform.”   

Corporate Momentum Milestones

• Enhancements to Kaseya’s security suite through Graphus acquisition and IT Complete product innovations. The acquisition of Graphus, an automated phishing defense solution, and the addition of new security offerings signal Kaseya’s continuous commitment to providing customers with the tools they need to deftly address any kind of cyber threat that comes their way. In 2020, Kaseya launched Spanning Dark Web Monitoring, a unique feature that not only backs up SaaS data, but also provides account takeover protection for Office 365 and G Suite accounts, and Passly, a three-in-one identity and access management (IAM) solution that combines single sign-on (SSO), multi-factor authentication (MFA) and password management.

• Shift to world-class, virtual experiences. Kaseya welcomed more than 2,100 attendees to 80+ sessions at Connect IT 2020, its global user conference that was held virtually for the first time ever last year. Without the constraints of ballrooms and physical meeting spaces, Kaseya blew the doors off Connect IT to bring attendees a show that was bigger and better than ever before. Additionally, Kaseya hosted its first virtual product launch in May, which kicked off the company’s quarterly product innovation cycles.

• Expansion of Automation Exchange. Kaseya’s crowd-sourced marketplace for all things automation now boasts over 13,000 contributors with thousands of scripts, reports and templates. The automation exchange is the largest “app store” of automation in the IT industry.

Innovations

• New Kaseya products and integrations eliminate the “space between,” a dilemma where IT professionals lose time and productivity when shifting between various functions and applications. Kaseya’s Fusion Mobile App is the only mobile IT management tool that integrates the functions of Kaseya’s remote monitoring and management (RMM) product, VSA, its professional services automation (PSA) solution, BMS, and IT documentation, IT Glue, into a single mobile application. Overall, Kaseya released over 78 different integrations across its IT Complete platform and is actively adding six to eight new integrations each quarter with the goal of making the lives of IT admins simpler and more efficient.

Key integrations included:

• BMS and IT Glue – New “Suggested Documentation” automatically assesses tickets and guides technicians to the solution, reducing the time it takes to close tickets.
• VSA and BMS – New Auto-Remediation reads ticket data and leverages automated RMM scripts to resolve issues without technician involvement.
• Unitrends and IT Glue – Automates backup and disaster recovery documentation so IT always has real-time information on the status of their data across all of their environments.
• VSA and IT Glue – Eliminates the need to perform separate management and documentation tasks by enabling remote control, scripting and context-aware information across both products

• Advanced backup capabilities from Unitrends automate backups to make management easier and ensure that your data is there when you need it.
  
  Unitrends Helix
  , an AI-powered, self-healing SaaS remediation platform, monitors and automatically fixes the most common issues facing IT administrators when managing backups. With Helix, Unitrends users can more confidently ensure their backups succeed and free up their time for more innovative or revenue-building initiatives. Unitrends Cloud Backup offers unparalleled file recovery and protection from viruses, hackers, corruption and accidental deletion with direct to cloud backup that eliminates the hassle of managing local backup storage. Conditional alerts reduce the noise of backup alerts to only the ones you need to take action on. With this feature, customers can specify conditions for alerts, giving them complete control to determine when administrators need to take action. Lastly, Unitrends Uniview empowers customers to manage all backups from a unified portal to perform appliance, direct to cloud, and Microsoft O365 application backups.

• To continue its commitment to providing customers with tools to navigate an ever-changing compliance space, Kaseya released Compliance Manager for NIST CSF, the industry’s first comprehensive audit, assessment and analysis solution that allows users to automate compliance processes and documentation according to the National Institute of Standards and Technology’s (NIST) Cyber Security Framework (CSF). In December 2020, Kaseya also added to its Compliance Manager capabilities with new support for the Department of Defense’s Cybersecurity Maturity Model Certification (CMMC) and an integration between Compliance Manager and IT Glue that makes documentation of compliance due diligence even more seamless. From the second quarter of 2020 to the year’s end, 798 new customers were using Compliance Manager.
• Two new RapidFire Tools solutions give administrators greater visibility into newly remote workforces. Early in 2020, RapidFire Tools Network Detective Work from Home (WFH) delivered a self-service portal that empowers employees working remotely to initiate a network and security scan that can be analyzed and documented by their companies’ IT support team before they connect to the corporate network. It then followed up with the RapidFire Tools Network Detective Microsoft Cloud Assessment Module, which is the fastest, most comprehensive Microsoft Cloud assessment solution on the market. It delivers critical visibility and enables better security and management of the Microsoft Cloud environment, including Microsoft Office 365 and Azure.

• IT Glue
  delivered enhancements to security and network visibility with:
  • The Vault – With the Vault, IT Glue’s client-side encryption/decryption feature, total control is in the hands of technicians. All passwords are encrypted locally and can only be decrypted by a user-specific passphrase, providing another layer of protection to IT Glue’s ironclad security.
  • Password Folder Security – This was one of IT Glue customers’ most requested features and now enhanced password folder security provides technicians the ability to easily organize passwords, eliminating the need to manage permissions. Password Folder Security saves valuable time, shifting the management of permissions to the folder level rather than being required to manage them separately.
  • Ports and Connected To – Automatically documents switch ports as well as connections between devices.
  • Active Directory Domain Role – See Domain Controllers on the Active Directory (AD) infrastructure. Easily troubleshoot, filter out devices that are members of the AD environment, and catch devices that have not yet been added to AD.
  • Virtual Network Topology within Network Glue – Automatically discover virtual networks in addition to routers, switches and firewalls.

Industry Recognition

Throughout 2020, Kaseya and its products received several industry awards highlighting its unparalleled innovation and leadership, including:

• TrustRadius 2020 TechCares Award – for helping its customers navigate the business challenges due to COVID-19 through the Kaseya Cares program.
• Top Workplaces in South Florida by the Sun Sentinel – based on employee feedback gathered through the Sun Sentinel’s survey administered by employee engagement technology partner Energage. The survey uniquely measured 15 drivers of engaged cultures that are critical to the success of any organization.
• 2020 American Cyber Award – for Innovative Product of the Year in Threat Detection – ID Agent, Passly
• CRN’s 100 Coolest Cloud Companies of 2020
• CRN’s 20 Coolest Data Protection Companies – for Unitrends Backup
• CRN’s 20 Coolest Cloud Storage Companies – for Unitrends Backup
• ChannelPro Readers’ Choice Award – for Best Remote Monitoring and Management Vendor, Bronze
• Top 50 SaaS CEOs of 2020 by The Software Report – 50 exceptional CEOs as selected by The Software Report based on a review across key areas including company performance, workplace culture, product strength and strategic decision-making.

About Kaseya

Kaseya® is the leading provider of IT and security management solutions for managed service providers (MSPs) and small to medium sized businesses (SMBs). Through its open platform and customer-centric approach, Kaseya delivers best in breed technologies that allow organizations to efficiently manage, secure, and backup IT. Kaseya IT Complete is the most comprehensive, integrated IT management platform comprised of industry-leading solutions from Kaseya, Unitrends, RapidFire Tools, Spanning Cloud Apps, IT Glue, ID Agent and Graphus. The platform empowers businesses to: command all of IT centrally; easily manage remote and distributed environments; simplify backup and disaster recovery; safeguard against cybersecurity attacks; effectively manage compliance and network assets; streamline IT documentation, and automate across IT management functions. Headquartered in Dublin, Ireland, Kaseya is privately held with a presence in over 20 countries. To learn more, visit www.kaseya.com.

Media Contacts

Katy Hoeper, PR Manager
Walker Sands
[email protected]

Tammy Hovey, VP of Corporate Communications
Kaseya
[email protected]

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) — Sequential Brands Group, Inc. (Nasdaq:SQBG), the owner of the William Rast brand, announced today that it has signed new partners for its women’s and men’s denim business. The Company has partnered with Omega Apparel to develop a new line of men’s denim and Millennial Apparel Group for women’s denim.

“We’re excited to create new collections of men and women’s denim. Since the William Rast brand launched in 2005, it has been known for delivering quality, fashion forward design and premium fit. We’re looking forward to the launch later this year and expanding the brand into additional distribution channels too,” said Arta Isovski, Senior Vice President of Sequential’s Lifestyle Division.

“We are very pleased to welcome William Rast as our newest partner. With our wide range of resources, we are confident that we can continue to grow William Rast into a meaningful, sustainable, fashion forward brand for us and our retail customers,” said Freddy Mamrout, Division Director of Millennial Apparel Group.

The new collections are expected to launch next year and will be sold at current distribution channels including department stores with a focus on expanding into new channels as well.

About Millennial Apparel Group

Millennial Apparel Group is an industry leading apparel manufacturer. A privately held, family owned company, that was founded on a simple ideal to provide the highest quality product at the best value in the market. Their world class talent and ability to generate trendsetting design, brought to life by their global manufacturing network and powered by their end to end operation. With over 80 in-house designers, they have experience and creativity to design and develop products with the latest trends.

About Omega Apparel

Omega Apparel is one of the leading, customer driven, specialty importers synonymous with denim and everyday lifestyle clothing. Founded in 1995, the Company is independently owned and operated.

About Sequential Brands Group, Inc.

Sequential Brands Group, Inc. (Nasdaq: SQBG) owns, promotes, markets, and licenses a portfolio of consumer brands in the active and lifestyle categories, including the William Rast brand. Sequential seeks to ensure that its brands continue to thrive and grow by employing strong brand management, and marketing teams. Sequential has licensed and intends to license its brands in a variety of consumer categories to retailers, wholesalers and distributors in the United States and around the world. For more information, please visit Sequential’s website at: www.sequentialbrandsgroup.com. To inquire about licensing opportunities, please email: [email protected].

Forward-Looking Statements

Certain statements in this press release and oral statements made from time to time by representatives of the Company are forward-looking statements (“forward-looking statements”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date hereof and are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. The Company’s actual results or actual events could differ materially from those stated or implied in forward-looking statements. Forward-looking statements include statements concerning revenue, plans, objectives, goals, strategies, expectations, intentions, projections, developments, future events, performance or products, underlying assumptions and other statements that are not historical in nature, including those that include the words “subject to,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “estimates,” “forecasts,” “projects,” “aims,” “targets,” “may,” “will,” “should,” “can,” “future,” “seek,” “could,” “predict,” the negatives thereof, variations thereon and similar expressions. Such forward-looking statements reflect the Company’s current views with respect to future events, based on what the Company believes are reasonable assumptions. Whether actual results will conform to expectations and predictions is subject to known and unknown risks and uncertainties, including: (i) risks and uncertainties discussed in the reports that the Company has filed with the Securities and Exchange Commission (the “SEC”); (ii) general economic, market or business conditions; (iii) continued market acceptance of the Company’s brands; (iv) changes in the Company’s competitive position or competitive actions by other companies; (v) licensees’ ability to fulfill their financial obligations to the Company; (vi) adverse effects on the Company and its licensees due to natural disasters, pandemic disease and other unexpected events, including the COVID-19 pandemic, and (vii) other circumstances beyond the Company’s control. Refer to the section entitled “Risk Factors” set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for a discussion of important risks, uncertainties and other factors that may affect the Company’s business, results of operations and financial condition. In addition, the global economic climate and additional or unforeseen effects from the COVID-19 pandemic amplify many of the foregoing risks. The Company’s stockholders are urged to consider such risks, uncertainties and factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Forward-looking statements are not, and should not be relied upon as, a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. As a result, actual outcomes and results may differ materially from those expressed in forward-looking statements. The Company is not under any obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Readers should understand that it is not possible to predict or identify all risks and uncertainties to which the Company may be subject. Consequently, readers should not consider such disclosures to be a complete discussion of all potential risks or uncertainties.

Media Contact:
Sequential Brands Group, Inc.
Katherine Nash
T: +1 512-757-2566
E: [email protected]

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (“Evoke” or the “Company”) (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced positive findings from the first market research for GIMOTI following its launch during the fourth quarter of 2020.

During December 2020, Evoke through its marketing partner, EVERSANA, conducted an ATU (Awareness, Trial, and Usage) Study, a quantitative survey to measure physician awareness, trial, and product usage, for GIMOTI. Approximately 104 total physician responses were captured. Survey respondents were split into three groups drawn from the healthcare practitioner (HCP) community; “target” gastroenterologists currently being called on by the field sales force (n = 61), other “non-target” gastroenterologists (n = 19), and primary care physicians (PCPs) who are not currently targeted for messaging (n = 24). Areas of interest that were queried included initial and future potential prescribing trends, and how HCPs viewed the suitability of GIMOTI in certain gastroparesis patient populations.

Key Findings:

• Indicated an intent to prescribe GIMOTI:
  • 79% of target gastroenterologists.
  • 89% of non-target gastroenterologists.
  • 50% of PCPs.
• Out of those target gastroenterologists indicating an intent to prescribe GIMOTI, 94% indicated GIMOTI would be “appropriate” to use in moderate to severe patients.
• A majority of each of the target and non-target gastroenterologists noted they intend to prescribe GIMOTI for both new and existing gastroparesis patients.
• Nineteen of all participating HCPs indicated that they have already written a prescription for GIMOTI.
  • HCPs indicated that the primary driver for prescribing GIMOTI was patients being switched to GIMOTI due to lack of efficacy of current treatments.

“While only a little over 10 weeks into our commercial launch, and occurring coincident with the pandemic environment and a holiday period, we are pleased with the ATU findings as they provide further direction for our commercial team and demonstrate that the GIMOTI message is hitting home, both with targeted and non-targeted healthcare care providers,” commented David Gonyer, R.Ph., Evoke Pharma President and CEO.

“Patients with diabetic gastroparesis often do not attain suitable relief from symptoms with oral treatments. This may be due to erratic absorption of orally administered drugs related to delayed gastric emptying or from vomiting up oral medications. Unfortunately, all traditional outpatient treatments used to manage symptoms of this disease are oral. GIMOTI is administered nasally, bypassing the GI system, with direct bloodstream delivery via the nasal membrane. This avoids the problem of unpredictable stomach emptying,” stated Richard McCallum, MD, Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center El Paso. “I’ve been waiting for an alternative treatment like this for a long time. It is a major step forward in the treatment of gastroparesis and it will help many of my patients.”

“We are pleased with the ATU results and encouraged with recent feedback our 27 Gastroenterology Care Specialists are receiving from providers,” added Chris Quesenberry, Chief Commercial Officer. “The results of the market research follow the positive reception we are hearing from doctors who desire an alternative to existing oral therapies. They indicate that a nasal route of administration that bypasses the GI tract makes sense for this underserved patient population. In 2021, we will continue to build on the commercial launch of GIMOTI to increase awareness and ensure that patients and their providers have access to this important brand.”

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.

About Gimoti™ (metoclopramide) nasal spray

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Important Safety Information

WARNING: TARDIVE DYSKINESIA

• Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.
• Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.
• Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use.

GIMOTI is not recommended for use in:

• Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.
• Moderate or severe hepatic impairment (ChildPugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.

GIMOTI is contraindicated:

• In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.
• When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation).
• In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.
• In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.
• In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.

Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery.
Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. 
These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About EVERSANA Life Science Services, LLC

EVERSANA™ is a leading provider of global services to the life science industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product lifecycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.

Safe Harbor Statement

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding: potential future prescribing trends for GIMOTI based on this survey of HCPs or the Company’s marketing efforts; and Evoke’s commercialization plans, including its plans to increase awareness and access to GIMOTI. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; the results of the ATU survey may not predict prescribing trends by doctors or acceptance by patients, and are not intended to reflect or imply actual prescriptions or sales to date; Evoke’s ability to obtain additional financing as needed to support its operations, including through the EVERSANA line of credit which is subject to certain customary conditions; the COVID-19 pandemic may disrupt Evoke’s and EVERSANA’s business operations impairing the ability to commercialize GIMOTI and Evoke’s ability to generate any product revenue; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to obtain and maintain intellectual property protection for GIMOTI; and other risks detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Contact:
The Ruth Group
Jan Medina, CFA
Tel: 646-536-7035
[email protected]

Media Contact:
The Ruth Group
Annika Parrish
Tel: 720-412-9042
[email protected]